Announcements Trials
Browse Landscape

Phase

Phase 2 29Phase 1/2 2Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × enzastaurin × Clear all
NCT00452413 2021-05-13

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Eli Lilly and Company

Phase 1/2 Completed
65 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00402116 2020-08-06

Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

Eli Lilly and Company

Phase 1/2 Completed
72 enrolled 19 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡